Cargando…

Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy

Background: Non-infectious uveitis represents a leading cause of visual impairment, and inflammation control represents a major priority in tackling visual acuity loss due to complications such as macular edema; different immunomodulatory drugs are currently being used, including anti-TNF-alpha Adal...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirani, Vittorio, Pelliccioni, Paolo, De Turris, Serena, Rosati, Alessandro, Franceschi, Alessandro, Pasanisi, Pierangelo, Gesuita, Rosaria, Nicolai, Michele, Mariotti, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074084/
https://www.ncbi.nlm.nih.gov/pubmed/32069898
http://dx.doi.org/10.3390/jcm9020510
_version_ 1783506758630637568
author Pirani, Vittorio
Pelliccioni, Paolo
De Turris, Serena
Rosati, Alessandro
Franceschi, Alessandro
Pasanisi, Pierangelo
Gesuita, Rosaria
Nicolai, Michele
Mariotti, Cesare
author_facet Pirani, Vittorio
Pelliccioni, Paolo
De Turris, Serena
Rosati, Alessandro
Franceschi, Alessandro
Pasanisi, Pierangelo
Gesuita, Rosaria
Nicolai, Michele
Mariotti, Cesare
author_sort Pirani, Vittorio
collection PubMed
description Background: Non-infectious uveitis represents a leading cause of visual impairment, and inflammation control represents a major priority in tackling visual acuity loss due to complications such as macular edema; different immunomodulatory drugs are currently being used, including anti-TNF-alpha Adalimumab. Methods: This was a monocentric observational study of 18 eyes of 18 patients with non-infectious uveitis treated with Adalimumab. The primary endpoint was the control of ocular inflammation. The secondary endpoints included the study of macular and choroidal thickness and architecture, visual acuity, changes in other treatments, and adverse effects. Results: Ocular inflammation was controlled at 12 months for 83.3% of patients. Central macular thickness improved from a median of 229.75 µm at baseline to 213 µm at 12 months, while choroidal thickness decreased by 11.54% at the end of the follow-up. A reduction of vasculitis on fluorescein angiography and of hyperreflective spots on optical coherence tomography was noted. Visual acuity also improved from 0.51 (logMAR) before treatment to 0.24 at more than 12 months (p = 0.01). A total of 11.1% of patients experienced side effects. Conclusion: Our study confirms the efficacy of adalimumab for the control of ocular inflammation, visual acuity preservation, and for corticosteroid sparing.
format Online
Article
Text
id pubmed-7074084
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70740842020-03-19 Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy Pirani, Vittorio Pelliccioni, Paolo De Turris, Serena Rosati, Alessandro Franceschi, Alessandro Pasanisi, Pierangelo Gesuita, Rosaria Nicolai, Michele Mariotti, Cesare J Clin Med Article Background: Non-infectious uveitis represents a leading cause of visual impairment, and inflammation control represents a major priority in tackling visual acuity loss due to complications such as macular edema; different immunomodulatory drugs are currently being used, including anti-TNF-alpha Adalimumab. Methods: This was a monocentric observational study of 18 eyes of 18 patients with non-infectious uveitis treated with Adalimumab. The primary endpoint was the control of ocular inflammation. The secondary endpoints included the study of macular and choroidal thickness and architecture, visual acuity, changes in other treatments, and adverse effects. Results: Ocular inflammation was controlled at 12 months for 83.3% of patients. Central macular thickness improved from a median of 229.75 µm at baseline to 213 µm at 12 months, while choroidal thickness decreased by 11.54% at the end of the follow-up. A reduction of vasculitis on fluorescein angiography and of hyperreflective spots on optical coherence tomography was noted. Visual acuity also improved from 0.51 (logMAR) before treatment to 0.24 at more than 12 months (p = 0.01). A total of 11.1% of patients experienced side effects. Conclusion: Our study confirms the efficacy of adalimumab for the control of ocular inflammation, visual acuity preservation, and for corticosteroid sparing. MDPI 2020-02-13 /pmc/articles/PMC7074084/ /pubmed/32069898 http://dx.doi.org/10.3390/jcm9020510 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pirani, Vittorio
Pelliccioni, Paolo
De Turris, Serena
Rosati, Alessandro
Franceschi, Alessandro
Pasanisi, Pierangelo
Gesuita, Rosaria
Nicolai, Michele
Mariotti, Cesare
Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy
title Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy
title_full Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy
title_fullStr Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy
title_full_unstemmed Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy
title_short Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy
title_sort intraocular inflammation control and changes in retinal and choroidal architecture in refractory non-infectious uveitis patients after adalimumab therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074084/
https://www.ncbi.nlm.nih.gov/pubmed/32069898
http://dx.doi.org/10.3390/jcm9020510
work_keys_str_mv AT piranivittorio intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy
AT pelliccionipaolo intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy
AT deturrisserena intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy
AT rosatialessandro intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy
AT franceschialessandro intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy
AT pasanisipierangelo intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy
AT gesuitarosaria intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy
AT nicolaimichele intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy
AT mariotticesare intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy